Product Description
Mechanisms of Action: V2 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Vantia
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Nocturia|Prostatic Hyperplasia
Phase 2: Nocturia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02537288 |
NCT02537288 | P1 |
Completed |
Nocturia |
2015-12-01 |
2024-11-27 |
||
NCT02440841 |
NCT02440841 | P1 |
Completed |
Nocturia |
2015-07-01 |
2019-03-20 |
Treatments |
|
NCT01330927 |
NCT01330927 | P1 |
Completed |
Nocturia|Prostatic Hyperplasia |
2011-07-01 |
2019-03-19 |
Treatments |
|
NCT01171391 |
NCT01171391 | P1 |
Completed |
Nocturia |
2010-11-01 |
2019-03-19 |
||
NCT00922740 |
NCT00922740 | P1 |
Completed |
Nocturia |
2009-07-01 |
2019-03-18 |
Treatments |
|
NCT00879216 |
NCT00879216 | P1 |
Completed |
Nocturia |
2009-05-01 |
2019-03-18 |
Treatments |
|
NCT01656239 |
NCT01656239 | P2 |
Completed |
Nocturia |
2013-08-01 |
2019-03-19 |
Treatments |
|
NCT01038843 |
NCT01038843 | P2 |
Completed |
Nocturia |
2010-07-01 |
2019-03-19 |
Treatments |
|
2008-003774-17 |
2008-003774-17 | P2 |
Completed |
Nocturia |
2009-02-02 |
2022-03-12 |
Treatments |
|
NCT00879138 |
NCT00879138 | P2 |
Completed |
Nocturia |
2009-02-01 |
2019-03-18 |
Treatments |
|
NCT02637960 |
EQUINOC | P3 |
Completed |
Nocturia|Prostatic Hyperplasia |
2017-07-01 |
2019-03-20 |
Recent News Events
Date |
Type |
Title |
|---|
